fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Cefadroxil

3 general benefit · 1 not a benefit

Apo-Cefadroxil · DIN 02240774 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Cefadroxil · DIN 02240774 Manufacturer: Apotex Inc.; listing date 2000-04-17 Daily cost (source): $1.1790 Health Canada: Marketed since 1999-08-31 · brand APO-CEFADROXIL · ATC J01DB05 CEFADROXIL · form Capsule · route Oral · ingredients CEFADROXIL 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Cefadroxil: Formulary list price $0.59 per unit (the source does not state the unit; exact figure $0.5895). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240774)

Source record
DIN 02240774: Apo-Cefadroxil Raw flags: sec3=Y Item: 081228036; group id 36; item number 0072; lccId None; manufacturer id APX Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.5895; ministry $0.5895 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240774 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64363
Interchangeable products
Duricef · DIN 00507245 · not recorded Jamp Cefadroxil · DIN 02544792 · $0.5895 Teva-Cefadroxil · DIN 02235134 · $0.5895
Shortage status: resolved shortage (ended February 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240774
Shortage record checked October 6, 2026

Jamp Cefadroxil · DIN 02544792 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Cefadroxil · DIN 02544792 Manufacturer: Jamp Pharma Corporation; listing date 2024-10-31 Daily cost (source): $1.1790 Health Canada: Marketed since 2024-08-27 · brand JAMP CEFADROXIL · ATC J01DB05 CEFADROXIL · form Capsule · route Oral · ingredients CEFADROXIL (CEFADROXIL MONOHYDRATE) 500 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Cefadroxil: Formulary list price $0.59 per unit (the source does not state the unit; exact figure $0.5895). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02544792)

Source record
DIN 02544792: Jamp Cefadroxil Raw flags: sec3=Y Item: 081228036; group id 36; item number 0072; lccId None; manufacturer id JPC Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.5895; ministry $0.5895 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544792 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103342
Interchangeable products
Apo-Cefadroxil · DIN 02240774 · $0.5895 Duricef · DIN 00507245 · not recorded Teva-Cefadroxil · DIN 02235134 · $0.5895
Shortage status: resolved shortage (ended June 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02544792
Shortage record checked October 6, 2026

Teva-Cefadroxil · DIN 02235134 · 500 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Cefadroxil · DIN 02235134 Manufacturer: Teva Canada Limited; listing date 2000-01-17 Daily cost (source): $1.1790 Health Canada: Marketed since 2012-04-17 · brand TEVA-CEFADROXIL · ATC J01DB05 CEFADROXIL · form Capsule · route Oral · ingredients CEFADROXIL (CEFADROXIL MONOHYDRATE) 500 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Cefadroxil: Formulary list price $0.59 per unit (the source does not state the unit; exact figure $0.5895). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02235134)

Source record
DIN 02235134: Teva-Cefadroxil Raw flags: sec3=Y Item: 081228036; group id 36; item number 0072; lccId None; manufacturer id TEV Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.5895; ministry $0.5895 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02235134 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=56852
Interchangeable products
Apo-Cefadroxil · DIN 02240774 · $0.5895 Duricef · DIN 00507245 · not recorded Jamp Cefadroxil · DIN 02544792 · $0.5895
Shortage status: resolved shortage (ended March 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02235134
Shortage record checked October 6, 2026

Duricef · DIN 00507245 · 500 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-02-05 — choose a marketed DIN from the same-category list.Discontinued February 5, 2009 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-02-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-02-05 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Duricef · DIN 00507245 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Daily cost (source): $1.1790 Health Canada: Cancelled post market since 2009-02-05 · brand DURICEF · ATC J01DB05 CEFADROXIL · form Capsule · route Oral · ingredients CEFADROXIL 500 MG · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Duricef: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00507245)

Source record
DIN 00507245: Duricef Raw flags: notABenefit=Y, sec3=Y Item: 081228036; group id 36; item number 0072; lccId None; manufacturer id BQU Source form: Cap; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00507245 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4470
Interchangeable products
Apo-Cefadroxil · DIN 02240774 · $0.5895 Jamp Cefadroxil · DIN 02544792 · $0.5895 Teva-Cefadroxil · DIN 02235134 · $0.5895
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00507245
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 5, 2009 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01D, J01DB): coverage varies; not interchangeable

  • Cephalexin (Ceporex): general benefit, not a benefit
  • Cefazolin (Cefazolin for Injection): not a benefit
  • Cefixime (Suprax): general benefit
  • Cefprozil (Ran-Cefprozil): general benefit, not a benefit
  • Ceftriaxone (Rocephin): general benefit, not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: skin and skin structure infections, uncomplicated urinary tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) • Skin and Skin Structure Infections caused by K. pneumoniae and species, P. mirabilis, Staph. aureus, Staph. epidermidis and Streptococcus species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph CLINDAMYCIN PHOSPHATE · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Listed, not a benefit (1) • Skin and skin structure infections including cellulitis, abscesses, and wound infections when caused by Streptococcus pyogenes, Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph TRIMETHOPRIM · Listed, not a benefit (2), General benefit (2) INDICATIONS AND CLINICAL USE For the treatment of acute, uncomplicated urinary tract infections due to susceptible strains of Escherichia coli and Klebsiella pneumoniae. PM: https://pdf.hres.ca/dpd_pm/00025165.PDF; date May 14, 2014; DIN 02243116; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA–CEFADROXIL (cefadroxil) is indicated for the treatment of the following infections when caused by susceptible strains of the organisms indicated: • Acute uncomplicated urinary tract infections when caused by E.coli, Klebsiella species and some strains of Proteus mirabilis. • Skin and skin structure infections caused by Staphylococcus aureus and/or Group A ß– hemolytic streptococci. • Acute pharyngitis–tonsillitis, when caused by Group A ß–hemolytic streptococci. TEVA-CEFADROXIL Page 3 of 28 • Lower respiratory tract infections, including pneumonia, caused by S. pneumoniae (D. pneumonia), S. Pyogenes (Group A ß–hemolytic streptococci), K. pneumoniae and S. aureus. Prior to and during therapy, appropriate bacteriological studies should be performed in order to identify and determine the susceptibility of the causative organism(s). To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEVA– CEFADROXIL and other antibacterial drugs, TEVA–CEFADROXIL should be use… https://pdf.hres.ca/dpd_pm/00056563.PDF PM date: May 20, 2020 Source product: TEVA-CEFADROXIL; DIN 02235134; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Duricef: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026